New research confirms that oral glucocorticoids—commonly prescribed steroids like prednisone—significantly increase the risk of Candidemia (bloodstream infections from Candida fungi) by up to 3.2-fold, particularly in immunocompromised patients. Published this week in The Journal of Infectious Diseases, the study analyzed 12,000 hospitalized cases and found the highest risk among those on high-dose regimens (>20 mg/day prednisone equivalent) for more than 14 days. The CDC warns this risk is underrecognized in outpatient settings, where glucocorticoids are often prescribed for autoimmune conditions like rheumatoid arthritis or asthma.
This matters because Candidemia kills 40% of hospitalized patients who develop it [1], and glucocorticoids are among the most widely prescribed drugs globally—with over 20 million U.S. prescriptions written annually. The mechanism? Steroids suppress immune surveillance of mucosal barriers (e.g., gut, oral cavity), while also altering glucose metabolism—a double hit for Candida colonization. Meanwhile, regional healthcare systems face divergent challenges: the NHS in the UK reports a 15% rise in fungal sepsis cases tied to steroid use, while the FDA has yet to update prescribing guidelines despite the data.
In Plain English: The Clinical Takeaway
Steroids + Candida = Dangerous Combo: Taking oral steroids like prednisone for more than 2 weeks triples your risk of a life-threatening fungal blood infection.
Not all steroids are equal: High doses (>20 mg/day prednisone equivalent) pose the greatest risk—low-dose regimens (e.g., for asthma) carry minimal increased risk.
Prevention is key: If you’re on long-term steroids, ask your doctor about antifungal prophylaxis (e.g., fluconazole) and strict oral hygiene.
Why Do Glucocorticoids Skyrocket Candidemia Risk?
The link between glucocorticoids and Candidemia stems from two interconnected mechanisms:
Immune suppression: Glucocorticoids bind to glucocorticoid receptors in immune cells, downregulating TNF-α and IL-1β—cytokines critical for neutrophil recruitment and fungal clearance [2]. A 2023 Cell Host & Microbe study showed that prednisone-treated mice had a 40% reduction in alveolar macrophage activity against Candida albicans.
Metabolic shift: Steroids induce insulin resistance, raising serum glucose levels. Candida thrives in hyperglycemic environments, as demonstrated in a 2025 Diabetologia trial where patients with poorly controlled diabetes on steroids had a 5.7x higher colonization rate in the gastrointestinal tract.
From Instagram — related to Clinical Infectious Diseases, Cell Host
The risk isn’t uniform: a Clinical Infectious Diseases analysis of 8,342 cases found that Candida auris—a multidrug-resistant strain—was 2.8x more likely to cause bloodstream infections in steroid users compared to C. albicans. This aligns with emerging data on C. auris‘s predilection for immunocompromised hosts [3].
Global Disparities: How Healthcare Systems Are Responding
Regulatory responses vary sharply by region, reflecting differences in prescription patterns and surveillance infrastructure:
Region
Prescription Volume (2024)
Reported Candidemia Cases Linked to Steroids
Regulatory Action
Key Barrier to Prevention
United States
20M+ annual prescriptions
12% of Candidemia cases (CDC 2025)
No updated FDA warnings (last guidance: 2018)
Lack of antifungal stewardship programs in outpatient clinics
United Kingdom (NHS)
15M+ annual prescriptions
15% rise in cases (2023–2025)
NHS England issued a “Green Light” alert in March 2026 for high-risk patients
Primary care physicians underestimating fungal risk in steroid users
India
50M+ annual prescriptions (highest global)
Data scarce; estimated 8–12% of ICU Candidemia cases
No national guidelines; reliance on empiric antifungal use
Limited access to echinocandins (first-line antifungal) in rural hospitals
The WorldHealth Organization highlighted this disparity in a May 2026 report, noting that low- and middle-income countries lack the diagnostic capacity to detect Candida infections early. “In settings where steroids are prescribed without antifungal prophylaxis, we’re essentially priming patients for sepsis,” said Dr. Leila Alavi, WHO’s fungal disease program lead.
Funding and Bias: Who Paid for This Research?
The study was funded by a $4.2 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), with additional support from the Burroughs Wellcome Fund. While NIAID has no financial ties to antifungal drug manufacturers, the Burroughs Wellcome Fund has historically funded research on Candida pathogenesis—though its role here was limited to data analysis.
Critically, the trial’s primary investigator, Dr. Rajesh Gandhi (Harvard Medical School), disclosed no conflicts of interest. However, a JAMA Network Open editorial last year flagged underreporting of fungal sepsis in steroid trials, suggesting industry-funded studies may downplay these risks [4]. This study’s independence from pharmaceutical influence strengthens its credibility.
Expert Voices: What Leading Researchers Say
“The magnitude of risk here—3.2-fold—is striking, but it’s not surprising. We’ve known for decades that steroids impair mucosal immunity, yet clinicians still treat them as a panacea for inflammation. The real tragedy is that many of these infections are preventable with simple measures like fluconazole prophylaxis.”
Approach to Candidemia, when to suspect and how to treat. – Weekly Webinar 23 Infectious Disease
“In Europe, we’ve seen a shift toward shorter steroid courses and closer monitoring in high-risk patients. The challenge now is getting this message to primary care physicians, who often lack training in fungal infections. Antifungal stewardship programs, like those in the Netherlands, could save thousands of lives.”
Contraindications & When to Consult a Doctor
Not everyone on glucocorticoids is at equal risk, but these groups should discuss alternatives or prophylaxis with their physician:
High-dose users: Doses equivalent to >20 mg/day prednisone for >14 days (e.g., 40 mg methylprednisolone). Risk level: Critical.
Immunocompromised patients: Those with HIV/AIDS, post-transplant, or on chemotherapy. Risk level: Severe.
Indwelling device users: Patients with central lines or urinary catheters. Risk level: Elevated.
Seek emergency care if you experience:
Fever >101°F (38.3°C) with chills
Severe abdominal pain or bloating
Confusion or difficulty breathing (signs of sepsis)
For those already on steroids, prophylactic fluconazole (200–400 mg weekly) has been shown in a 2025 Clinical Infectious Diseases trial to reduce Candidemia risk by 68% in high-risk patients [5]. However, this should only be initiated under medical supervision due to potential drug interactions.
What Happens Next? The Path Forward
The next critical steps will likely include:
Regulatory updates: The FDA and EMA are expected to issue revised warnings on glucocorticoid labeling within 12–18 months, following the pattern set by the 2018 Candidemia risk alerts for broad-spectrum antibiotics.
Clinical guidelines: The Infectious Diseases Society of America (IDSA) is reviewing its Candidemia guidelines to incorporate steroid risk stratification, with a draft expected by late 2026.
Diagnostic expansion: Rapid Candida antigen tests (e.g., BD MAX system) are being rolled out in U.S. hospitals, though accessibility remains limited in low-resource settings.
For now, the message is clear: glucocorticoids remain invaluable for managing autoimmune and inflammatory diseases, but their use must be weighted against fungal risk, especially in prolonged or high-dose regimens. Patients should advocate for shared decision-making with their providers—asking whether alternatives (e.g., non-steroidal anti-inflammatory drugs, biologics) or shorter courses could mitigate this preventable threat.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider before altering treatment regimens.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
